GlassScriptPhysician profile
Aesha A Parikh
NPI 1285310334
$7,580.05
in general payments reported to CMS, 2019-2025
33 companies · $3,383 in 2025
The $3,383 reported for 2025 was more than what 96% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,020 · 2024: $3,178 · 2025: $3,383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,553 · Education: $27.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,552.97 |
| Education | $27.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,670.14 | 2023-2025 | |
| Janssen Biotech, INC. | $1,102.00 | 2023-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $943.09 | 2023-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $631.33 | 2023-2025 | |
| Qol Medical, LLC | $582.00 | 2023-2025 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $526.02 | 2023-2025 | Xifaxan, Trulance |
| Ardelyx, INC. | $230.54 | 2024-2025 | Ibsrela |
| Pfizer INC. | $207.39 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $172.44 | 2024-2025 | Iqirvo |
| Celltrion USA INC. | $138.56 | 2024-2025 | Vegzelma, Zymfentra |
| Phathom Pharmaceuticals, INC. | $135.50 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $135.25 | 2023-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $135.00 | 2023 | Zeposia |
| Alnylam Pharmaceuticals INC. | $129.01 | 2024-2025 | Givlaari |
| Janssen Scientific Affairs, LLC | $105.09 | 2024 | Stelara |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $96.90 | 2023-2024 | Dificid |
| Lilly USA, LLC | $89.15 | 2023-2025 | Omvoh, Zepbound |
| Madrigal Pharmaceuticals | $86.92 | 2025 | Rezdiffra |
| Celgene Corporation | $78.08 | 2023-2024 | Zeposia |
| Enterra Medical, INC. | $52.35 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $39.96 | 2023 | Rebyota |
| Vivus LLC | $31.80 | 2024 | Qsymia |
| Daiichi Sankyo INC. | $29.07 | 2024 | Injectafer |
| Organon LLC | $28.06 | 2023-2024 | Hadlima |
| Fresenius Kabi USA, LLC | $27.57 | 2024 | Idacio |
| Novo Nordisk INC | $25.97 | 2025 | Wegovy |
| Sandoz INC. | $25.39 | 2025 | Hyrimoz |
| Amgen INC. | $24.25 | 2023 | Avsola, Amjevita |
| Medtronic, INC. | $22.93 | 2025 | Eleview |
| Braintree Laboratories, INC. | $21.87 | 2023 | Suflave |
| Ironwood Pharmaceuticals, INC | $19.52 | 2024 | |
| Blueprint Medicines Corporation | $19.30 | 2025 | Ayvakit |
| Nestle Healthcare Nutrition INC. | $17.60 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aesha Parikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.